These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25700648)

  • 41. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose optimization of infliximab in patients with rheumatoid arthritis.
    Alten R; van den Bosch F
    Int J Rheum Dis; 2014 Jan; 17(1):5-18. PubMed ID: 24472261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
    Conaghan PG; Quinn MA; O'Connor P; Wakefield RJ; Karim Z; Emery P
    Arthritis Rheum; 2002 Jul; 46(7):1971-2; author reply 1973. PubMed ID: 12124886
    [No Abstract]   [Full Text] [Related]  

  • 44. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.
    Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA;
    Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
    Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
    Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I; Koó E; Seszták M; Gergely P
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Genitourinary malignancies and rheumatoid arthritis].
    Boegemann M; Alten R; Aringer M; Zastrow S
    Z Rheumatol; 2016 Feb; 75(1):54-62. PubMed ID: 26786167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Osteonecrosis and monoarticular rheumatoid arthritis treated with intra-articular adalimumab.
    Kobak S
    Mod Rheumatol; 2008; 18(3):290-2. PubMed ID: 18286352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
    Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
    Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
    Castrejón I; Gibson KA; Pincus T
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review.
    Chessa E; Piga M; Floris A; Congia M; Cangemi I; Mathieu A; Cauli A
    BioDrugs; 2021 Mar; 35(2):175-186. PubMed ID: 33595833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of liposomes in treatment of rheumatoid arthritis: quo vadis.
    Kapoor B; Singh SK; Gulati M; Gupta R; Vaidya Y
    ScientificWorldJournal; 2014; 2014():978351. PubMed ID: 24688450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.].
    Yamaoka K
    Clin Calcium; 2018; 28(5):678-685. PubMed ID: 29731464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [New drugs in rheumatology].
    Müller-Ladner U; Lange U
    Internist (Berl); 2014 Apr; 55(4):377-81. PubMed ID: 24577342
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Gender-specific differences in the diagnosis and treatment of inflammatory rheumatic diseases].
    Albrecht K; Strangfeld A
    Inn Med (Heidelb); 2023 Aug; 64(8):744-751. PubMed ID: 36877237
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [In-label treatment of inflammatory joint diseases].
    Kneitz C; Fiehn C
    Z Rheumatol; 2018 Sep; 77(7):559-568. PubMed ID: 29968102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Established medications : new areas of application].
    Kötter I; Henes JC
    Z Rheumatol; 2013 Nov; 72(9):853-66. PubMed ID: 24193188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.